Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REG1 versus bivalirudin in patients undergoing PCI
NL-OMON40245Phase 3Active, not recruiting
- Sponsor
- Regado Biosciences
- Start
- Feb 2014
- Modality
- Small Molecules, Peptides, RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronary arteriosclerosis comparing REG1 Anticoagulation System with Bivalirudin (2 arms). Primary endpoint: Primary efficacy endpoint. Started Feb 2014; status: active, not recruiting.
02
Drugs
pegnivacoginbivalirudin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON40245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40245.